Hetal Mistry is an Oncology physician. OpenAlex indexes 24 publications with 237 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5115 Centre Ave Fl 2
Pittsburgh, PA 152321301
Telephone
412-692-4724Provider last certified this registry record 27 Aug 2025.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Anti-androgens100%Erleada100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Abstract P1-08-25: The differential diagnosis of a large breast mass in a young woman
Clinical Cancer Research
2025 - Recurrent High-Risk Neuroblastoma in an Adult Woman 28 Years following Curative Treatment
Case Reports in Oncology
2025 - Assessing Anaphylaxis: Improving Residents' Identification of a Life-Threatening Condition via a Focused Didactic and Case-Based Discussion.
PubMed
2025 - 1063 Outcomes in immune-related adverse events in melanoma patients with liver metastasis treated with immune checkpoint inhibitors: a retrospective analysis
Regular and Young Investigator Award Abstracts
2025 - A patient with newly diagnosed breast cancer found to have mosaic <i>TP53</i> likely pathogenic variant
CA A Cancer Journal for Clinicians
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”